Hearts & Minds Blog

Investor Day and July Meetings Recap

Alex Schwartz

Senior Director, Investor Relations

Hi, I’m Alex Schwartz and I recently joined Esperion as Head of Investor Relations.  Prior to joining Esperion, I was a publishing analyst at Stifel Nicolaus, got an MBA in finance from Boston College, and was a trader at Schonfeld Securities.  I will be focusing on providing knowledge on the LDL-C lowering market, cardiovascular drug development, and everything bempedoic acid as well as Esperion Therapeutics.  Most recently, on July 10th, we hosted an Investor Day.  A replay of the webcast is available here and the… more

A Closer Look – June 2018

Tim Mayleben

President and Chief Executive Officer

As we approach the halfway point in 2018, our Lipid Management Team remains confident and encouraged by the consistently positive results from four Phase 2 and Phase 3 clinical studies of bempedoic acid, all of which met their primary endpoints. In this blog post, I’d like to take the opportunity to reinforce the strength of our program as well as clear up any concerns or misinterpretations of the data, particularly as they relate to the safety and tolerability of bempedoic acid. Esperion and the bempedoic… more

Key Insights from March 2018 ACC: CLEAR Outcomes Looking Even CLEARer After ODYSSEY – Updated ICER Cost-Effectiveness Analysis A Win for Patients and for the Bempedoic Acid Franchise

Tim Mayleben

President and Chief Executive Officer

Our Lipid Management Team attended the 67th Annual Scientific Session of the American College of Cardiology (ACC) in Orlando this past weekend.  As is tradition following one of the major cardiology meetings, we want to provide our key insights as they relate to Esperion and our bempedoic acid-based therapies. The standout this year was the presentation of top-line results from ODYSSEY Outcomes (ODYSSEY), a cardiovascular outcomes trial (CVOT) for the injectable PCSK9i, alirocumab, along with the announcement by the Institute for Clinical and Economic Review… more

Help with Understanding Liver Function Test Increases: From the Lipid Management Team

Tim Mayleben

President and Chief Executive Officer

We recently announced positive results from our first pivotal phase 3 study (Study 4 or the 048 study) of bempedoic acid.  This was a significant milestone for our Lipid Management Team on our path of developing, gaining approval for, and commercializing bempedoic acid and the bempedoic acid / ezetimibe combination pill.  I’m incredibly proud of our team! In Study 4, bempedoic acid lowered LDL-cholesterol by 28%, reduced hsCRP by 33% and was observed to be safe and well-tolerated in 269 ASCVD or high-CV risk patients… more

The History of LDL-Cholesterol with Dr. Antonio Gotto | Beyond Statins: The Future of Cholesterol Lowering Treatments

Tim Mayleben

President and Chief Executive Officer

Antonio M. Gotto, Jr., MD, DPhil

Dean Emeritus, Weill Cornell Medicine, and Provost for Medical Affairs Emeritus, Cornell University

In Part I and Part II of this series we explored the evolution of LDL-cholesterol: from the early days of its discovery to the statin era boom. Now, we sit down again with cardiovascular and lipids specialist, Dr. Antonio M. Gotto, Jr, for the third and final installment of “The History of LDL-Cholesterol” to get his perspective on the future of LDL-cholesterol lowering. Read on for highlights from our conversation on the evolution of cholesterol-lowering treatments; the implications of bempedoic acid-based therapies for physicians, patients… more